Antiviral Agent Therapy Optimization in Special Populations of COVID-19 Patients
Open Access
- 1 July 2020
- journal article
- review article
- Published by Taylor & Francis in Drug Design, Development and Therapy
- Vol. ume 14, 3001-3013
Abstract
Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is now a global outbreak of disease. The antiviral treatment acts as one of the most important means of SARS-CoV-2 infection. Alteration of physiological characteristics in special populations may lead to the change in drug pharmacokinetics, which may result in treatment failure or increased adverse drug reactions. Some potential drugs have shown antiviral effects on SARS-CoV-2 infections, such as chloroquine, hydroxychloroquine, favipiravir, lopinavir/ritonavir, arbidol, interferon alpha, and remedsivir. Here, we reviewed the literature on clinical effects in COVID-19 patients of these antiviral agents and provided the potential antiviral agent options for pregnant women, elderly patients, liver or renal dysfunction patients, and severe or critically ill patients receiving renal replacement therapy or ECMO after SARS-CoV-2 infection.Keywords
This publication has 62 references indexed in Scilit:
- Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in HumansAntimicrobial Agents and Chemotherapy, 2013
- A Case of Severe Hydroxychloroquine-Induced Retinal Toxicity in a Patient with Recent Onset of Renal Impairment: A Review of the Literature on the Use of Hydroxychloroquine in Renal ImpairmentCase Reports in Ophthalmological Medicine, 2012
- Determinants of drug absorption in different ECMO circuitsIntensive Care Medicine, 2010
- Molecular dynamic simulations analysis of ritronavir and lopinavir as SARS-CoV 3CLpro inhibitorsJournal of Theoretical Biology, 2008
- SARS: Systematic Review of Treatment EffectsPLOS Medicine, 2006
- Evidence of transplacental passage of hydroxychloroquine in humansArthritis & Rheumatism, 2002
- Minimal dose of aerosolized interferon-alpha in human subjects: biological consequences and side-effectsEuropean Respiratory Journal, 1996
- Stability of Recombinant Consensus Interferon to Air‐Jet and Ultrasonic NebulizationJournal of Pharmaceutical Sciences, 1995
- Pharmacokinetics of inhaled recombinant and natural alpha interferonThe Lancet, 1991
- Accumulation of Chorio-retinotoxic Drugs in the Foetal EyeNature, 1970